| Intrinsic Valuation of: STARHEALTH | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 11 | Market Cap | ₹249B | |||||
| 2021 | - | - (-) | P/E Ratio | 39 | Total Asset | ₹220B | |||||
| 2022 | ₹-76M | - (-) | Net Income | ₹6B | Total Debt | ₹5B | |||||
| 2023 | ₹12B | 16359.6% (14182.4%) | EBITDA | - | Total Liab | ₹149B | |||||
| 2024 | ₹12B | -3.5% (-15.7%) | Opr Margin | - | Debt/Equity | 0.07 | |||||
| 2025 | ₹13B | 9.2% (-4.9%) | PreTax Margin | - | BV/Share | 121 | |||||
| 5Y Average FCF | ₹9B | 5455.1% (4720.6%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (25.0%) | ||||||||||
| 2026 | ₹16B | MBG Intrinsic Value | ₹97 | ||||||||
| 2027 | ₹20B | ||||||||||
| 2028 | ₹25B | ||||||||||
| 2029 | ₹32B | ||||||||||
| 2030 | ₹40B | ||||||||||
| 2031 | ₹49B | ||||||||||
| Terminal Value | ₹1,028B | Net Worth/Share | ₹121 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹805B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹7B | ₹1,373 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹5B | WACC | 7.3% | 1,194 | 1,289 | 1,404 | 1,545 | 1,723 | |||
| Equity Value | ₹807B | 7.4% | 1,183 | 1,276 | 1,388 | 1,526 | 1,699 | ||||
| Shares Outstanding | 587,785,984 | 7.4% | 1,172 | 1,263 | 1,373 | 1,508 | 1,676 | ||||
| 7.9% | 1,071 | 1,147 | 1,236 | 1,343 | 1,474 | ||||||
| DCF Intrinsic Value | ₹1,373 | 8.4% | 985 | 1,048 | 1,122 | 1,209 | 1,314 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||